Verastem GAAP EPS of -$0.50 beats by $0.02, revenue of $17.54M beats by $0.7M
Source: SeekingAlpha
2026-03-04 16:05:33 ET
More on Verastem
- Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC
- Verastem Q4 2025 Earnings Preview
- Verastem posts preliminary 2025 revenue, plans clinical updates in 2026
- Seeking Alpha’s Quant Rating on Verastem
- Historical earnings data for Verastem
Read the full article on Seeking Alpha
For further details see:
Verastem GAAP EPS of -$0.50 beats by $0.02, revenue of $17.54M beats by $0.7M
Verastem Inc.
NASDAQ: VSTM
VSTM Trading
-2.34% G/L:
$6.27 Last:
375,559 Volume:
$6.36 Open:
VSTM Latest News
VSTM Stock Data
$424,027,638
66,108,246
1.4%
15
N/A
Biotechnology & Life Sciences
Healthcare
US
Needham
